ImmuPharma (LON:IMM) Shares Down 10% - Here's What Happened

Key Points

• ImmuPharma's shares fell by 10% during mid-day trading, dropping to GBX 11.25 ($0.15) with a decline in trading volume compared to its average session.
• The company reported negative earnings per share of GBX (0.38) for the last quarter, with forecasts indicating a current year EPS of -339.00.
• ImmuPharma is a specialty biopharmaceutical company focused on developing peptide-based therapeutics for autoimmune diseases, including its lead program, Lupuzor™ for Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) fell 10% during trading on Monday . The stock traded as low as GBX 10.51 ($0.14) and last traded at GBX 11.25 ($0.15). 11,107,625 shares traded hands during mid-day trading, an increase of 30% from the average session volume of 8,513,286 shares. The stock had previously closed at GBX 12.50 ($0.17).

ImmuPharma Trading Up 9.5%

The company's fifty day simple moving average is GBX 4.46 and its 200 day simple moving average is GBX 3.33. The firm has a market capitalization of £60.47 million, a P/E ratio of -1,359.55 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.